Full Press Release Details
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7th Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Jefferies London Healthcare Conference
Fireside Chat: Tuesday, November 19, 2024, at 11:30 a.m. GMT in London, UK
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Tuesday, November 19
7th Annual Evercore HealthCONx Conference
Fireside Chat: Tuesday, December 3, 2024, at 1:20 p.m. EST in Coral Gables, Florida
Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
Please find a link to the webcast here
Management will also participate in one-on-one meetings on Tuesday, December 3
Citi Global Healthcare Conference
Management will participate in one-on-one meetings on Wednesday, December 4 in Miami, Florida
A webcast of both fireside chats can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Karin Hellsvik, Foghorn Therapeutics Inc.